Inhibition of human topoisomerase II by antineoplastic benzazolo[3,2-a]quinolinium chlorides

Molecular and Cellular Biochemistry

Volumn 178, Issue 1-2, 1998, Pages 203-212

  Vivas Mejía, Pablo E ^a   Cox, Osvaldo ^a   González, Fernando A ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

Antitumor; Cancer; DNA intercalator

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); KINETOPLAST DNA; QUINOLINE DERIVATIVE;

ARTICLE; DNA SUPERCOILING; ENZYME INHIBITION; ENZYME PURIFICATION; HISTIOCYTIC LYMPHOMA; HUMAN; HUMAN CELL; PLASMID;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DNA TOPOISOMERASES, TYPE II; DNA, SUPERHELICAL; ETOPOSIDE; HUMANS; NUCLEIC ACID CONFORMATION; QUINOLINIUM COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0031888721     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006847615575     Document Type: Article

References (43)

1. Kornberg A, Baker T: DNA Replication. Second edition. New York: W.H. Freeman and Company, 1992
2. Liu LF: DNA topoisomerases: enzymes that catalyze the breaking and rejoining of DNA. Crit Rev Biochem 15: 1-24, 1983
3. Wang JC: DNA topoisomerases. Annu Rev Biochem 65: 635-693, 1996
4. Sinha KB: Topoisomerase inhibitors: A review of their therapeutic potential in cancer. Drug 49: 11-19, 1995
5. Gellert M: DNA topoisomerase. Annu Rev Biochem 50: 879-910, 1981
6. Hohn C, Goto T, Wang JC, Botstein D: DNA topoisomerase II is required at the time of mitosis in yeast. Cell 41: 553-563, 1985
7. Ishimi Y, Sugasana K, Hanaoka F, Eki T, Hurwitz J: Topoisomerase II plays an essential role as a swivelase in the late stage of SV40 chromosome replication in vitro. J Biol Chem 267: 462-466, 1992
8. Shamu CE, Murray AW: Sister chromatid separation in frog egg extracts required DNA topoisomerase II activity during anaphase. J Cell Biol 117: 921-934, 1992
9. Vassetzky YS, Alghisi GC, Gasser SM: DNA topoisomerase II mutations and resistance to anti-tumor drugs. BioEssays 17: 767-774, 1995
10. Liu LF: DNA Topoisomerases poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989
11. Corbett AH, Osheroff N: When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 6: 584-597, 1993
12. Long BH, Musial ST, Brottain MG: Comparison of cytotoxicity and DNA breakage activity of congeners of epipodophyllotoxin including VP-16.213 and VM-26: A quantitative structure-activity relationship. Biochemistry 23: 1183-1188, 1984
13. Sinha BK, Haim N, Dusre L: DNA strand breaks produced by etoposide (VP-16.213) in sensitive and resistant human breast tumor cells: Implications for the mechanism of action. Cancer Res 48: 5096-5100, 1988
14. Nelson EM, Tewey KM, Liu LF: Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4 -(9-acridinylamino)-methanesulfon-m-aniside. Proc Natl Acad Sci USA 81: 1361-1365, 1984
15. Schneider E, Lawsen PA, Ralph RK: Inhibition of protein synthesis reduces the cytotoxicity of 4 -(9-acridinylamino)methanesulfon-m-anisidide in a murine mastocytoma cell line. Biochem Pharmacol 38: 263-269, 1989
16. Zwelling LA, Michaels S, Erickson LC, Ungerleider RS, Nicols M, Kohn KW: Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4 -(9-acridinylamino) methanesulfon-m-aniside and adryamycin. Biochemistry 20: 6553-6563, 1981
17. González FA, Llende M, Báez A, Ortiz JR: The antitumor drug 3-nitrobenzothaizolo[3,2-a]quinolinium chloride (NBQ): Effects on lens regeneration and interaction with DNA of Notophtalmus viridescens. Differentiation 86: 125-129, 1987
18. Báez A, González FA, Vázquez D, Waring MJ: Interaction between a 3-nitrobenzothiazolo[3,2-a]quinolinium antitumor drug and deoxyribo-nucleic acid. Biochem Pharmacol 32: 2089-2094, 1983
19. Báez A, Riou JF, LePecq JB, Riou G: Interaction of DNA intercalator 3-nitrobenzothiazolo[3,2-a]quinolinium with DNA topoisomerases: A possible-mechanism for its biological activity. Mol Pharmacol 37: 377-382, 1989
20. Vivas-Mejía PE, Rodríguez-Cabán JL, Díaz-Velázquez M, Hernández-Pérez MG, Cox O, Gonzalez FA: DNA binding-independent anti-proliferative action of benzazolo[3,2-a]quinolinium DNA intercalators. Mol Cell Biochem, 1997, in press
21. Riou JF, Gabillot M, Philippe M, Schrevel J, Riou G: Purification and characterization of plasmodium berghei DNA topoisomerase I and II: Drug action, inhibition of decatenation and relaxation, and stimulation of DNA cleavage. Biochemistry 25: 1471-1478, 1986
22. Miller KG, Liu LF, Englund PT: A homogeneous type II DNA topoisomerase from HeLa cell nuclei. J Biol Chem 256: 9334-9339, 1981
23. Spitzner JR, Chung IK, Muller MT: Eukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats. Nucleic Acids Res 18: 1-11, 1990
24. Marini JC, Miller KG, Englund PT: Decatenation of kinetoplast DNA by topoisomerases. J Biol Chem 255: 4976-4979, 1980
25. Riou GF, Yot P: Heterogeneity of the kinetoplast DNA molecules of Trypanosome cruzi. Biochemistry 16: 2390-2396, 1977
26. Trask DK, Muller MT: Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc Natl Acad Sci USA 85: 1417-1421, 1988
27. Shaw JL, Blanco J, Mueller GC: A simple procedure for isolation of DNA, RNA and protein fractions from cultured animal cells. Anal Biochem 65: 125-131, 1975
28. Muller MT, Mehta VB: DNase I hypersensitivity is independent of endogenous topoisomerase II activity during chicken erythrocyte differentiation. Mol Cell Biol 8: 3661-3669, 1988
29. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979
30. Cox O, Jackson H, Vargas VA, Báez A, Colón JI, González BC, de León M: Synthesis and biological activity of benzothiazolo and benzoxazolo[3,2-a]quinolinium salts. J Med Chem 25: 1378-1381, 1982
31. Chen J, Rauch CA, While JH, Englund PT, Cozzarelli NR: The topology of the kinetoplast DNA network. Cell 80: 61-69, 1996
32. Borde V, Duguet M: In vivo topoisomerase II cleavage sites in the ribosomal DNA of Physarum polycephalum. Annu Rev Biochem 35: 5787-5795, 1996
33. Snapka RM, Powelson MA, Strayer JM: Swiveling and decatenation of replicating simian virus 40 genomes in vivo. Mol Cell Biochem 8: 515-521, 1988
34. Casiano-Torres CA, Báez A: Effects of the antitumor drugs 3-nitro-benzothiazolo[3,2-a]quinolinium and fagaronine on nucleic acid and protein synthesis. Biochem Pharmacol 35: 679-685, 1986
35. Reinert KE: DNA stiffening and elongation caused by the binding of ethidium bromide. Biochim Biophys Acta 319: 135-139, 1973
36. Poddevin B, Riou JF, Lavelle F, Pommier Y: Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol 44: 767-774, 1993
37. Clark AJ: Mode of Action of Drugs on Cells. Arnold Publishing, London 1993
38. Ames M, Powis G, Kovach J: Pharmocokinetics of Anticancer Agents in Humans. Elsevier Science Publishers B.V., Amsterdam, 1983, pp 3-28
39. Sutherland RM: Cell and environment interactions in tumor micro-regions: The multicell spheroid model. Science 240: 177-184, 1988
40. Beere HM, Chresta CM, Hickman A: Selective inhibition of topoisomerase II by ICRF-193 does not support role for topoisomerase II activity in the fragmentation of chromatine during apoptosis of human leukemia cells. Mol Pharmacol 49: 842-851, 1996
41. 2+ complex on DNA: A new paradigm for the structure of a drug-DNA complex and implications for the structure of the quinoline bacterial gyrase-DNA complex. J Med Chem 38: 408-424, 1995
42. Drake FH, Hofmann GA, Mong SM, Bartus JO, Hertzberg RP, Johnson RK, Mattern MR, Mirabelli CK: In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 49: 2578-2583, 1989
43. Alegria AE, Cox O, Santiago V, Colon M, Reyes Z, Zayas L, Rivera LA, Dumas JA: Reductive activation of benzazolo[3,2-a]quinolinium chlorides. Free Radical Biol Med 15: 49-56, 1993